How Effective Is HBOT for Diabetic Foot Ulcers?
A 2024 meta-analysis of 14 studies found that HBOT increased complete wound healing rates by 17 to 21 times in diabetic foot ulcer patients compared to standard care alone. That matters because 15-25% of the 37 million Americans with diabetes will develop a foot ulcer, and these ulcers are the leading cause of non-traumatic amputation in the US, with roughly 185,000 amputations performed each year.
Part of the BaricBoost HBOT Data series. Cite as: “HBOT for Diabetic Foot Ulcers: 2026 Healing Rate & Amputation Prevention Data,” BaricBoost.com, July 2026.
HBOT for diabetic patients targets the fundamental pathophysiology of these wounds: compromised blood flow and oxygen delivery to the extremities. When standard wound care fails after 30+ days, HBOT is the most evidence-supported adjunctive therapy available.
Headline Numbers
| Outcome | Effect | Source |
|---|---|---|
| Complete wound healing | RR 2.39 (95% CI 1.87-3.05) | Oley et al. 2024 |
| Major amputation reduction | RR 0.31 (95% CI 0.18-0.52), a 69% cut | Oley et al. 2024 |
| Complete healing at 1 year | 52% HBOT vs 29% placebo | Londahl et al. 2010 (HODFU) |
| Ulcer healing odds | OR 4.00 (95% CI 1.54-10.44) | Cruz et al. 2021 |
What Do Meta-Analyses Show for HBOT and Diabetic Foot Ulcers?
The evidence base for HBOT in diabetic wound care is the strongest of any HBOT indication, supported by multiple meta-analyses and the Cochrane Collaboration (comprehensive wound healing data).
2025 Network Meta-Analysis (Yang et al.)
The most comprehensive comparison to date analyzed 34 RCTs and 2,268 diabetic foot ulcers across all gas therapies.1
- HBOT ranked first for healing rate: SUCRA=0.814
- HBOT ranked first for wound area reduction rate: SUCRA=0.730
- Greater area reduction when treatment exceeded 6 weeks
2024 Wagner Grade Meta-Analysis (Oley et al.)
Stratified analysis across 14 studies examining HBOT by wound severity grade.2
| Outcome | Result | P-value |
|---|---|---|
| Overall wound healing (RR) | 2.39 (95% CI 1.87-3.05) | <0.00001 |
| Major amputation reduction (RR) | 0.31 (95% CI 0.18-0.52) | <0.00001 |
| Wagner Grade II healing (RR) | 21.11 (95% CI 3.05-146.03) | 0.002 |
| Wagner Grade III healing (RR) | 19.58 (95% CI 2.82-135.94) | 0.003 |
| Wagner Grade IV healing (RR) | 17.53 (95% CI 2.45-125.44) | 0.004 |
Read the Wagner-grade healing numbers with care. The relative risks of 17 to 21 look enormous, but their 95% confidence intervals are very wide (for Grade II, 3.05 to 146.03), which reflects small numbers of healed wounds in the pooled control arms. The direction of benefit is consistent and significant, but the precise magnitude at each grade is uncertain. Treat these as large but imprecise, not as literal 20-fold effects.
2021 Cruz et al. Meta-Analysis (11 RCTs, 668 patients)
- Ulcer healing: OR=4.00 (95% CI 1.54-10.44)4
- Major amputation risk: OR=0.53 (95% CI 0.32-0.90)4
- Wound area reduction at 2 weeks: 23.19% greater in HBOT group (95% CI 14.86-31.52)4
A separate 2021 meta-analysis by Sharma and colleagues pooled 14 studies and found HBOT reduced major amputations by roughly 40% while improving healing, consistent in direction with Oley and Cruz.3
What Do Individual Trials and Real-World Data Show?
HODFU Trial (Londahl et al. 2010)
Gold-standard double-blind RCT, 94 patients with chronic diabetic foot ulcers.6
- Complete healing at 1 year: 52% HBOT vs 29% placebo (P=0.03)
- Per-protocol (35+ sessions): 61% vs 27% (P=0.009)
- Number needed to treat: approximately 4-5 patients to heal one additional wound
Lalieu et al. 2023: Largest Single-Center Retrospective
774 treatment courses across all chronic wound types.7
- 61.0% healed; 22.9% partially healed; 5.3% deteriorated
- Wound surface area: median decreased from 4.4 cm² to 0.2 cm² (P<0.01)
- Quality of life improved: 60 to 75 on 100-point scale (P<0.01)
- Median sessions: 39 (IQR 23-51); median cost: EUR 9,188
- Fewer than 30 sessions and severe arterial disease associated with negative outcomes
“In the largest real-world outcomes study of HBOT for chronic wounds (774 treatment courses), wound surface area shrank from a median of 4.4 cm² to just 0.2 cm², while patient quality of life scores improved from 60 to 75 out of 100.”
Lalieu et al. 2023, Advances in Skin & Wound Care
National registry data supports the pattern. The US Hyperbaric Oxygen Therapy Registry, which tracks real-world wound outcomes across many centers, was built specifically to demonstrate the quality and value of HBOT in wound care.8
Which Wagner Grades Qualify for HBOT?
| Grade | Description | HBOT Eligible? |
|---|---|---|
| 0-2 | Intact skin through deep ulcer (no abscess) | No (standard care first) |
| 3 | Deep ulcer with abscess/osteomyelitis | Yes (Medicare covered) |
| 4 | Partial foot gangrene | Yes (Medicare covered) |
| 5 | Whole foot gangrene | Yes (emergency) |
What Does the HBOT Protocol Look Like?
- Pressure: 2.0-2.4 ATA in a hard chamber
- Session duration: 90-120 minutes at treatment pressure (full session details)
- Frequency: Once daily, 5 days per week
- Initial course: 30 sessions, with reassessment
- Maximum: Typically 60 sessions for diabetic wounds
Because outcomes drop off sharply below 30 sessions, completing the course is closely tied to whether the wound heals and whether an amputation is avoided.
How Much Does HBOT Cost, and Does Insurance Cover It?
HBOT for diabetic foot ulcers is one of the few indications where insurance coverage is well established. Medicare covers under NCD 20.29 for Wagner grade 3+ wounds after failed standard wound therapy, using CPT code 99183.
The cost-effectiveness case is strong: treating 4-5 patients at a total HBOT cost of $60,000-$150,000 prevents one amputation costing $140,000+ in immediate surgery costs and $500,000+ in lifetime care.5 Diabetic foot ulcers are also the model indication in the broader oxygen therapy for diabetic foot ulcers literature.
Sources
- Yang J, et al. Comparative efficacy of gas therapy for diabetic foot ulcers using network meta-analysis. PeerJ. 2025;13:e19571. DOI: 10.7717/peerj.19571
- Oley MH, et al. Hyperbaric Oxygen Therapy for Diabetic Foot Ulcers Based on Wagner Grading: systematic review and meta-analysis. Plastic and Reconstructive Surgery Global Open. 2024. DOI: 10.1097/GOX.0000000000005692
- Sharma R, et al. Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer: a systematic review and meta-analysis of 14 studies. Scientific Reports. 2021;11:2189. DOI: 10.1038/s41598-021-81886-1
- Cruz D, Oliveira-Pinto J, Mansilha A. The role of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers. International Angiology. 2021;40(4):327-340. DOI: 10.23736/S0392-9590.21.04722-2
- Chuck AW, et al. Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers. Int J Technol Assess Health Care. 2008;24(2):178-183. DOI: 10.1017/S0266462308080252
- Londahl M, et al. Hyperbaric Oxygen Therapy Facilitates Healing of Chronic Foot Ulcers in Patients with Diabetes (HODFU trial). Diabetes Care. 2010;33(5):998-1003. DOI: 10.2337/dc09-1754
- Lalieu RC, et al. Hyperbaric Oxygen Therapy for Nonhealing Wounds: a long-term retrospective cohort study (774 courses). Advances in Skin & Wound Care. 2023. DOI: 10.1097/01.ASW.0000922696.61546.31
- Fife CE, Eckert KA. The Hyperbaric Oxygen Therapy Registry: Driving Quality and Demonstrating Value. Undersea & Hyperbaric Medicine. 2018. DOI: 10.22462/01.02.2018.1
- Centers for Medicare & Medicaid Services. National Coverage Determination 20.29: Hyperbaric Oxygen Therapy. cms.gov
- Rahman NHA, et al. Use of hyperbaric oxygen therapy in chronic diabetic wound. Medical Journal of Malaysia. 2019;74(5):418-424. PMID: 31649219
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
